Title |
Building a Comprehensive Genomic Program for Hepatocellular Carcinoma
|
---|---|
Published in |
World Journal of Surgery, January 2011
|
DOI | 10.1007/s00268-010-0954-x |
Pubmed ID | |
Authors |
Theresa R. Harring, Jacfranz J. Guiteau, N. Thao T. Nguyen, Ron T. Cotton, Marie‐Claude Gingras, David A. Wheeler, Christine A. O’Mahony, Richard A. Gibbs, F. Charles Brunicardi, John A. Goss |
Abstract |
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, causing approximately 660,000 deaths worldwide annually. The preferred treatment of HCC is surgical resection or orthotopic liver transplantation (OLT) for patients meeting specific criteria. For patients outside these criteria, options are limited and include medical therapy, radiofrequency ablation, chemoembolization, or palliative measures, and these result in poor outcomes. Various centers at Baylor are elucidating the genomics of HCC to improve treatment options, with a focus on three etiologies: hepatitis C virus, hepatitis B virus, and non-viral. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
United States | 1 | 2% |
Germany | 1 | 2% |
Brazil | 1 | 2% |
Unknown | 51 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 10 | 18% |
Researcher | 10 | 18% |
Student > Ph. D. Student | 7 | 13% |
Student > Master | 4 | 7% |
Professor > Associate Professor | 3 | 5% |
Other | 4 | 7% |
Unknown | 17 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 27% |
Agricultural and Biological Sciences | 7 | 13% |
Biochemistry, Genetics and Molecular Biology | 6 | 11% |
Immunology and Microbiology | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Other | 4 | 7% |
Unknown | 18 | 33% |